墨西哥的研究者宣称,一种治疗肝硬变的新疗法能显著增加病人5年和10年的存活率。他们对100例各种原因引起的肝硬变病人进行了对照试验并随访达14年。Kershenobid等以前曾研究过一种广泛用于治疗痛风的药物秋水仙碱(colchicine),证明它能减轻四氯化碳所致老鼠肝硬变的肝脏纤维化改变和肝功能不良。54例接受秋水仙碱和46例 Mexican researchers claim that a new treatment for cirrhosis can significantly increase the patient’s 5-year and 10-year survival rates. They compared 100 patients with cirrhosis caused by various causes and were followed up for 14 years. Kershenobid et al. Have previously studied colchicine, a drug widely used to treat gout, and demonstrated its ability to reduce liver fibrosis and liver dysfunction induced by carbon tetrachloride in cirrhotic mice. 54 cases received colchicine and 46 cases